Media Releases

2021

24/11/2021

FDA advises regulatory pathway for PromarkerD in US

23/11/2021

PromarkerD distribution network expands to Britain

16/11/2021

New Directors appointed to Company Board

05/11/2021

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

03/11/2021

Proteomics International awarded $100,000 manufacturing funding

12/08/2021

Proteomics International contracts Biotem to manufacture PromarkerD test kits

11/08/2021

Diabetes treatment lowers PromarkerD risk score: Results presented at Australasian Diabetes Congress

04/08/2021

Proteomics to collaborate to validate test for endometriosis

22/07/2021

Proteomics engages Abcam to manufacture PromarkerD reagents

16/07/2021

Diabetes treatment lowers PromarkerD risk score: Results to be presented at Australasian Diabetes Conference

28/06/2021

World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years

10/06/2021

CCO and CFO appointed to bolster executive team

18/05/2021

Proteomics secures major analytical services contract

13/05/2021

Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update

29/04/2021

Proteomics International files US FDA 513(g) regulatory submission

1
2
3
4
5
6
7
8
9